Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Novo Nordisk A/S Common Stock
(NY:
NVO
)
54.30
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Aug 20, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novo Nordisk A/S Common Stock
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
92
93
Next >
US Judge Upholds FDA Decision To Remove Wegovy, Ozempic From Shortage List In Move Against Compounding Pharmacies
June 18, 2025
The judge said that the FDA had appropriately weighed supply and demand data for the drugs and properly removed them from the shortage list, Reuters reported.
Via
Stocktwits
Topics
Lawsuit
Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study
June 18, 2025
Scholar Rock's apitegromab helped preserve muscle mass during tirzepatide-induced weight loss, improving overall body composition in Phase 2 trial.
Via
Benzinga
Novo Nordisk Just Improved Its Weight-Management Pipeline: Is the Stock a Buy?
June 18, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Why Novo Nordisk Stock Sank by Nearly 4% Today
June 16, 2025
Via
The Motley Fool
Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue Opportunities
June 17, 2025
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TNDM),(NYSE:NVO),(NASDAQ:PODD),(NYSE:MDT) EQNX::TICKER_END
Via
FinancialNewsMedia
Ozempic Patent Expires In Canada After Novo Nordisk Fails To Pay $450 Fee: 'It's The Second-Largest Semaglutide Market In The World,' Says Sandoz CEO Richard Saynor
June 16, 2025
A simple oversight could end up costing Danish pharma giant Novo Nordisk A/S (NYSE: NVO) billions in potential losses on its blockbuster weight-loss and diabetes drug, Ozempic.
Via
Benzinga
Topics
Intellectual Property
Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue Opportunities
June 17, 2025
From
FN Media Group LLC
Via
GlobeNewswire
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
June 16, 2025
Via
The Motley Fool
1 Growth Stock Down 9% to Buy Right Now
June 14, 2025
Via
The Motley Fool
Novo Nordisk Moves Amycretin Into Phase 3 Trials For Weight Management, Becomes Europe's Largest Company
June 13, 2025
Novo Nordisk will begin phase 3 trials for amycretin in early 2026 following promising weight loss data and regulatory discussions.
Via
Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today
June 13, 2025
Via
Benzinga
Why Novo Nordisk Stock Pumped Higher on Thursday
June 12, 2025
Via
The Motley Fool
Novo Nordisk’s Plan To Start Late-Stage Trial Of Investigational Obesity Drug Amycretin In 2026 Gets Retail Talking
June 12, 2025
The decision to advance the study of subcutaneous and oral Amycretin into the late stage is based on feedback received from regulators following mid-stage studies.
Via
Stocktwits
10 Health Care Stocks With Whale Alerts In Today's Session
June 12, 2025
Via
Benzinga
Nvidia Just Partnered With A Weight-Loss Giant, But It's Not About Pills
June 12, 2025
Nvidia teams up with Novo Nordisk and IQVIA to boost AI-powered drug development and streamline complex pharmaceutical workflows.
Via
Benzinga
4 Dividend Stocks to Double Up on Right Now
June 12, 2025
The stock market is a place where people tend to panic when things go on sale. Instead, buy the dip on these four fabulous dividend winners.
Via
The Motley Fool
Topics
Artificial Intelligence
2 Unstoppable Stocks to Consider Buying, Even Amid Market Volatility
June 12, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Government
Should You Buy UnitedHealth Stock Instead of Novo Nordisk Stock?
June 12, 2025
Via
The Motley Fool
McDonald's Just Got Hammered By Weight-Loss Drugs — Twice
June 11, 2025
McDonald's faces a potential decline in sales due to the weight loss medications. Other fast-food chains like Domino's and KFC are also at risk, while Taco Bell and Chipotle are better positioned.
Via
Benzinga
Nvidia Extends AI Reach In Europe With Alliances
June 11, 2025
Nvidia announced a flurry of alliances with European companies and governments that extend its influence in AI across the continent.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Government
Novo Nordisk’s $812M Deal With Deep Apple Lifts Retail Mood, Chatter Spikes To High Levels
June 11, 2025
Separately, chip-maker Nvidia also announced a collaboration with Novo Nordisk to accelerate drug discovery efforts through innovative AI use cases.
Via
Stocktwits
Topics
Artificial Intelligence
Economy
Novo Nordisk, Deep Apple Launch Drug Discovery Alliance For Weight Loss Oral Therapies
June 11, 2025
Novo Nordisk and Deep Apple ink a deal to develop oral therapies targeting a novel GPCR for cardiometabolic diseases, including obesity.
Via
Benzinga
Why Novo Nordisk Stock Just Popped
June 10, 2025
Novo Nordisk stock has multiple catalysts that could soon reverse is slide.
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
June 10, 2025
Via
Benzinga
2 Weight Loss Drug Stocks That Are Screaming Buys in June
June 10, 2025
These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing next-generation offerings.
Via
The Motley Fool
Why Novo Nordisk Stock Eked Out a Win on Monday
June 09, 2025
Via
The Motley Fool
Obesity Newcomer Metsera, Up 23%, Enters The Ring With A Punch
June 09, 2025
The company is planning to soon begin combination studies, testing two of its drugs in weight loss.
Via
Investor's Business Daily
Topics
Bankruptcy
Eli Lilly's Obesity Drug Success Spurs Japanese Biotech's Anti-Muscle-Wasting Combo Therapy
June 09, 2025
Chugai plans to pair its muscle-preserving drug with Eli Lilly's orforglipron, addressing muscle loss in obesity care as the market expands rapidly.
Via
Benzinga
Hims & Hers Stock Is Soaring Again. But Should You Buy the Stock?
June 08, 2025
Via
The Motley Fool
Topics
Supply Chain
With Novo Nordisk's CEO Out, Wall Street Wants an American Leader
June 07, 2025
With its stock plummeting over the past year, Novo Nordisk is waving goodbye to its top executive. What might the future hold for the weight-loss drug kingpin?
Via
MarketBeat
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
92
93
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.